A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Inclusion Criteria:

- Male or female subjects, age 18 years or older

- Histologically or cytologically confirmed diagnosis of selected locally advanced or
metastatic solid tumors

- Must have failed at least 1 prior treatment regimen for locally advanced or metastatic
disease or be intolerant to treatment or refuse standard treatment

Exclusion Criteria:

- Laboratory and medical history parameters not within protocol-defined range

- Participation in any other study in which receipt of an investigational study drug
occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose

- Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1,
anti-PD-L1, and any other antibody or drug specifically targeting T-cell
co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway
targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)

- Receipt of any anticancer medication in the 21 days prior to receiving the first dose
of study medication

- Has an active or inactive autoimmune process

- Evidence of interstitial lung disease or active, non-infectious pneumonitis

- Prior radiotherapy within 2 weeks of initiating treatment; Must have recovered from
all radiation-related toxicities, not require corticosteroids, and not have had
radiation pneumonitis

- Untreated central nervous system (CNS) metastases or CNS metastases that have
progressed

- Currently pregnant or breastfeeding